Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Linagliptin + Metformin
Jentadueto
Not routinely available
SMC (841/13)
29/03/2023
Indication
For the treatment of adult patients with type 2 diabetes mellitus. SMC restriction: to use in patients for whom a combination of linagliptin and metformin is an appropriate choice of therapy and these fixed-doses are considered appropriate.
Therapeutic Area
Endocrine system
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
2.5mg/850mg and 2.5mg/1000mg film-coated tablets
Comments
-
Link to Advice
Advice Published
11/02/2013
SMC Submission Type
Abbreviated
SMC Status
Restricted